What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

CBT, Bossan Enter Clinical Collaboration

The license agreement will allow companies to develop their respective assets in combination with each other

CBT Pharmaceuticals (CBT) and Zhejiang Bossan Pharmaceutical Co., Ltd (Bossan) have entered into a clinical collaboration and license agreement to develop their respective assets in combination with each other. 

 
The license agreement grants CBT exclusive, worldwide rights outside of Greater China to develop and commercialize ES-072, Bossan’s novel epidermal growth factor receptor (EGFR) inhibitor, in combination with CBT’s proprietary c-Met inhibitor (CBT-101) and anti-PD1 antibody (CBT-501).

“CBT and Bossan share the desire to pool our respective development compounds on an exclusive, worldwide basis to develop safe and efficacious regimens that may lead to approval for the treatment of a variety of cancers,” said Guo-Liang Yu, PhD, CBT global chief executive officer and Venture Partner, OrbiMed. “As demonstrated by our commitment to evaluate combination therapy with the recent announcement of our APOLLO program, we continue to investigate our assets in combination with other plausible agents with sound mechanistic and scientific rationale, potentially yielding promising results in the clinic.”

“Bossan is committed to reinforcing the foundation of lifesaving breakthroughs with new ideas.  CBT’s assets have shown promising preclinical and early stage clinical data, and we believe that the synergy of our combined assets may lead to improved outcomes for solid tumor cancer patients,” added Bossan chief executive officer, Dr. Hongguang Xia.

CBT and Bossan intend to jointly develop a collaboration product and conduct joint clinical trials of CBT’s c-Met inhibitor (CBT-101), and/or anti-PD1 antibody (CBT-501), in combination with Bossan’s EGFR inhibitor (ES-072). Under the terms of the agreement, CBT will be responsible for conducting clinical trials globally outside of Greater China. Both a Joint Steering Committee and Joint Clinical Development Subcommittee will be formed to oversee and coordinate research, development, manufacturing, regulatory and commercial activities.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters